Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473315 | 0.88 | EPHX2 (0.40) | NR1H2EPHX2USP2SMN1; SMN2PIK3R1 | |
| SCHEMBL22469470 | 0.85 | PIK3R1 (0.41) | NR1H2EPHX2USP2SMN1; SMN2PIK3R1 | |
| SCHEMBL1003155 | 0.85 | USP2 (0.44) | NR1H2EPHX2USP2SMN1; SMN2PIK3R1 | |
| SCHEMBL30713619 | 0.82 | NR1H2 (0.43) | NR1H2EPHX2USP2SMN1; SMN2EPHX1 | |
| SCHEMBL425587 | 0.81 | EPHX2 (0.36) | NR1H2EPHX2USP2SMN1; SMN2EPHX1 | |
| SCHEMBL28865052 | 0.80 | SYK (0.44) | SMN1; SMN2 | |
| SCHEMBL56916 | 0.80 | TDP1 (0.41) | EPHX1TDP1 | |
| SCHEMBL23120825 | 0.80 | CYP4F2 (0.39) | EPHX2PIK3R1PIK3CATDP1PIK3CD | |
| SCHEMBL5521873 | 0.77 | P2RX7 (0.42) | EPHX1TDP1 | |
| SCHEMBL1368840 | 0.77 | P2RX7 (0.40) | EPHX1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-11-11 | — | — | US | disclosed |
| EP-3971187-B1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2025-05-07 | — | — | EP | disclosed |
| CN-111201021-B | Chroman monocyclic beta-lactams for the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118496221-A | Chroman monocyclic beta-lactams for the treatment of bacterial infections | 默沙东有限责任公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3691639-B1 | CHROMANE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-116444515-A | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-115974897-A | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-112368283-B | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11433055-B2 | Chromane monobactam compounds for the treatment of bacterial infections | MERCK SHARP & DOHME LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| EP-2178874-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| WO-2009010488-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, CYP4A11, CYP11B1 | NR1H2 83/4885EPHX2 1053/4885USP2 4521/4885 |
| US-11433055-B2 | Chromane monobactam compounds for the treatment of bacterial infections | MGAM, MGAM2, CMBL | NR1H2 1031/4885EPHX2 1363/4885USP2 3598/4885 |
| US-12466823-B2 | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | RET, REL, GOT1 | NR1H2 182/4885EPHX2 2287/4885USP2 4562/4885 |
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | NR1H2 945/4885EPHX2 1479/4885USP2 1176/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | NR1H2 945/4885EPHX2 1479/4885USP2 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.